Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data

Critical Reviews in Oncology/hematology
Giannis MountziosChristos A Papadimitriou

Abstract

Lung carcinogenesis is considered to be the result of composite environmental, genetic and epigenetic changes. Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the "timing" of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells. Although loss of cell-cycle control is the crucial molecular event in both types, the mechanism by which it provokes oncogenesis differs significantly between SCLC and NSCLC. Importantly, some of these molecular events, including DNA-damage response and epidermal growth factor receptor (EGFR) mutations are valuable in predicting response to conventional chemotherapy or molecular-targeted agents as well as in the prognosis of patients that harbor these alterations. In the current review we report on the best characterized histopathologic and genetic changes in NSCLC and SCLC in relation to each histological subtype and we discuss their predictive and prognost...Continue Reading

References

Jun 18, 1997·Journal of the National Cancer Institute·L MaoW K Hong
Feb 4, 1999·The Annals of Thoracic Surgery·J M SiegfriedR J Landreneau
Feb 5, 2000·Seminars in Surgical Oncology·E M TolozaS G Swisher
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·J E StauntonT R Golub
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BhattacharjeeM Meyerson
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·M E GarberI Petersen
Nov 27, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J NiklińskiL Chyczewski
Dec 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·Bey-Dih ChangIgor B Roninson
Jul 16, 2002·Nature Medicine·David G BeerSamir Hanash
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Peter KripplHellmut Samonigg
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Aug 14, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Rafael RosellBarbara Roig
Dec 12, 2003·Drugs of Today·Rafael RosellGuillermo López-Vivanco
May 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Russell D PettyGraeme I Murray
Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D IslaP Lianes
Aug 5, 2004·Journal of the National Cancer Institute·Federico CappuzzoLucio Crinò
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wei ZhouDavid C Christiani
Nov 13, 2004·The Lancet Oncology·Ed Susman
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sae-Won HanNoe Kyeong Kim
Feb 17, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Mustafa ErmanJean-Charles Soria
Feb 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey A EngelmanLewis C Cantley
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tetsuya MitsudomiYasushi Yatabe
Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Apr 15, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M-C Etienne-GrimaldiG Milano
Apr 27, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H Cortes-FunesM Taron
May 5, 2005·Journal of the National Cancer Institute·Federico CappuzzoMarileila Varella-Garcia
May 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Eunice L KwakDaniel A Haber
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sunil SinghalSteven M Albelda
Jun 15, 2005·Expert Opinion on Pharmacotherapy·Kenji Tamura, Masahiro Fukuoka
Jul 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toshimi TakanoTomohide Tamura
Jul 15, 2005·The New England Journal of Medicine·Ming-Sound TsaoFrances A Shepherd
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico CappuzzoFred R Hirsch
Oct 13, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T DutuJ-C Soria
Nov 17, 2005·British Journal of Cancer·F CappuzzoM Varella-Garcia
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert L YauchLukas C Amler

❮ Previous
Next ❯

Citations

May 11, 2011·International Journal of Clinical Oncology·Yushi ZhaoZhong-Zheng Zhu
Dec 14, 2011·PloS One·Eva M Galan-MoyaRicardo Sánchez-Prieto
Jul 8, 2011·Journal of Cancer Research and Clinical Oncology·Carolina B MüllerFábio Klamt
Feb 14, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Valeska Aguiar de OliveiraFabio Klamt
Jul 24, 2012·Critical Reviews in Oncology/hematology·María SerenoEnrique Casado Sáenz
Apr 13, 2012·Critical Reviews in Oncology/hematology·Fadi S FarhatAli Shamseddine
Feb 12, 2013·Translational Oncology·Alice PasiniDaniele Calistri
Feb 22, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Giannis Mountzios, Kostas N Syrigos
Jun 13, 2015·Cancer Control : Journal of the Moffitt Cancer Center·Farah K Khalil, Soner Altiok
Nov 4, 2017·The Analyst·Marcus T Cicerone, Charles H Camp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sheila R Alcantara LlagunoLuis F Parada
Respirology : Official Journal of the Asian Pacific Society of Respirology
Masaki TomitaToshio Onitsuka
© 2022 Meta ULC. All rights reserved